Home   ->   news   ->   Press Releases

Press Releases

2014

News Archives: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004

2014/10/30
WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax

2014/10/23
WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S. FDA

2014/10/22
Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China

2014/10/21
WuXi PharmaTech Schedules Third-Quarter 2014 Earnings Release

2014/10/01
WuXi PharmaTech Laboratory Testing Division Expands in U.S. With Acquisition of XenoBiotic Laboratories, Inc.

2014/09/30
WuXi PharmaTech Announces Appointment of William R. Keller to Board

2014/08/18
WuXi Facility Passes FDA Inspection for Manufacture of API

2014/08/13
WuXi PharmaTech Announces Second-Quarter 2014 Results

2014/08/08
WuXi PharmaTech Announces Appointment of Walter Kwauk to Board

2014/06/23
WuXi AppTec Webinar on Breakthrough Drugs Draws Strong Attendance

2014/06/20
WuXi PharmaTech Toxicology Facility in Suzhou Passes FDA Inspection

2014/05/28
WuXi PharmaTech Begins Operation of New High-Potency API Laboratory

2014/05/23
Targos Molecular Pathology GmbH and WuXi PharmaTech to Collaborate in Clinical Biomarker Services and Pathology Training in China

2014/05/21
WuXi PharmaTech Toxicology Facility in Suzhou Passes OECD GLP Inspection

2014/05/14
WuXi PharmaTech Announces First-Quarter 2014 Results

2014/05/13
WuXi PharmaTech Completes Construction of New Biosafety Testing Facility in Suzhou

2014/05/12
WuXi PharmaTech Completes Construction of New Materials Characterization Facility in St. Paul

2014/05/08
WuXi PharmaTech Begins Construction of New R&D and cGMP Manufacturing Campus in Changzhou

2014/05/05
FDA Approves Ibalizumab Manufactured by WuXi PharmaTech for Treatment of Patients on Expanded Access

2014/05/01
WuXi PharmaTech Receives 2013 Lilly Global Supplier Award

2014/04/30
WuXi PharmaTech Facilities for Late - and Commercial-Stage Analytical and Stability Testing and Clinical-Trial Materials Manufacturing Pass FDA Audit

2014/04/29
WuXi PharmaTech Breaks Ground on New Cell Therapy Manufacturing Facility

2014/04/15
WuXi PharmaTech Announces Management Appointments: Dr. Steve Yang Joins Company as EVP and Chief Operating Officer; Edward Hu Named Chief Investment Officer and Remains Chief Financial Officer

2014/04/07
WuXi PharmaTech Receives Honorable Mention at 2014 ISPE Facility of the Year Awards

2014/04/01
WuXi PharmaTech Corporate Venture Fund Invests in TruTag Security Platform for Drug Safety

2014/03/11
WuXi PharmaTech and Pacific Biomarkers Announce Collaboration

2014/03/10
WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System

2014/03/05
WuXi PharmaTech Announced Fourth-Quarter and Full-Year 2013 Results

2014/02/27
WuXi PharmaTech Announces Appointment of Dr. Hua Mu to Head Product Development Service and Partnership Business Unit

2014/02/10
WuXi PharmaTech Schedules Fourth-Quarter and Full-Year 2013 Earnings Release

2014/01/14
WuXi PharmaTech Provides Update of 2013 Financial Guidance, to Present at J.P. Morgan Healthcare Conference